-
-
-
-
-
-
-
Bristol Myers Squibb Announces Early Participation Results and Early Settlement of Tender Offers for Up to an Aggregate Purchase Price of Up to $4.0 Billion
-
-
-
-
-
-
-
Bristol-Myers Squibb Completes Acquisition of Celgene, Creating a Leading Biopharma Company
-
-
-
-
-
-
-
Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes
-
-
-
-
-
-
-
Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes
-
-
-
-
-
-
-
Celgene Reports Second Quarter 2019 Operating and Financial Results
-
-
-
-
-
-
-
Bristol-Myers Squibb (BMY) is Planning Divestiture of OTEZLA to Get FTC Clearance for Celgene (CELG) Deal
-
-
-
-
-
-
-
Celgene Stockholders Approve Proposed Acquisition by Bristol-Myers Squibb
-
976,271 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All